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Simple Summary: The sensitivity to PARP inhibitors (PARPi) is related to tumor-specific defects in
homologous recombination (HR) and extends beyond BRCA1/2-related deficiencies. A robust method
to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance. In this study,
we evaluated the use of a functional test (the RECAP test) for the identification of HRD ovarian
carcinomas. Forty-nine epithelial ovarian carcinomas (EOC) were analyzed by the RECAP test.
Thirty-nine of these tumors were of the high-grade serous (HGSOC) histologic subtype. Ten out of
these 39 HGSOC specimens showed HRD (26%), whereas ovarian carcinomas of other histologic
subtypes (n = 10) were all HR-proficient (HRP). Eight out of 9 sequenced HRD tumors showed
pathogenic BRCA1/2 variants or BRCA1 promoter hypermethylation. This study shows that the
RECAP test is a reliable and rapid test to identify functional deficiencies in HR and a good alternative
to DNA-based HRD tests.
Abstract: Recent studies have shown that the efficacy of PARP inhibitors in epithelial ovarian
carcinoma (EOC) is related to tumor-specific defects in homologous recombination (HR) and extends
beyond BRCA1/2 deficient EOC. A robust method with which to identify HR-deficient (HRD)
carcinomas is therefore of utmost clinical importance. In this study, we investigated the proficiency of
a functional HR assay based on the detection of RAD51 foci, the REcombination CAPacity (RECAP)
test, in identifying HRD tumors in a cohort of prospectively collected epithelial ovarian carcinomas
(EOCs). Of the 39 high-grade serous ovarian carcinomas (HGSOC), the RECAP test detected 26%
(10/39) to be HRD, whereas ovarian carcinomas of other histologic subtypes (n = 10) were all
HR-proficient (HRP). Of the HRD tumors that could be sequenced, 8/9 showed pathogenic BRCA1/2
variants or BRCA1 promoter hypermethylation, indicating that the RECAP test reliably identifies
HRD, including but not limited to tumors related to BRCA1/2 deficiency. Furthermore, we found a
trend towards better overall survival (OS) of HGSOC patients with RECAP-identified HRD tumors
compared to patients with HRP tumors. This study shows that the RECAP test is an attractive
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alternative to DNA-based HRD tests, and further development of a clinical grade RECAP test is
clearly warranted.
Keywords: epithelial ovarian carcinoma; homologous recombination deficiency; RECAP test; RAD51;
BRCA1; BRCA2
1. Introduction
Surgical cytoreduction combined with platinum-based chemotherapy has traditionally been the
standard of care in the treatment of epithelial ovarian carcinoma (EOC) patients [1,2]. However, a series
of recent clinical trials showed that Poly (ADP-Ribose) Polymerase inhibitor (PARPi) as maintenance
treatment of EOC patients with platinum-sensitive cancers results in significant improvement of
both progression-free survival (PFS) and overall survival (OS) in newly diagnosed and recurrent
EOC [3–11]. This led to FDA and EMA approval of various PARPi as maintenance therapy in patients
with platinum-sensitive EOC, both in the primary and recurrent setting. Although the presence of
pathogenic variants in BRCA1 or BRCA2 is the best genetic predictor for a good clinical response to
PARPi therapy, multiple studies have shown that PARPi efficacy is also observed in patients with
non-BRCA1/2-deficient carcinomas [4,5,9,12]. Since current evidence suggests that a deficiency in
homologous recombination (HR) underlies sensitivity to PARPi, a search for biomarkers that correlate
with HR Deficiency (HRD) was initiated with the aim of developing a single method that can identify
all patients who could potentially benefit from PARPi treatment [13–16] (Table S1).
Most of the currently available HRD tests are DNA-based. Using gene-specific analyses,
the percentage of HRD high-grade serous ovarian carcinomas (HGSOC) is estimated to be as high as
50% [17]. In addition to the presence of pathogenic variants in BRCA1 and BRCA2 (20%), inactivation
of other genes involved in the HR pathway (6%) and the epigenetic silencing of BRCA1 (10%) or
RAD51C (3%) have also been reported in HGSOC [13,17,18]. The prevalence of HRD in other histologic
subtypes of EOCs such as low grade serous, endometrioid, clear cell, and mucinous OC is still
unclear [19]. In addition to gene-specific analyses, more complex DNA-based approaches, such
as the identification of ‘genomic scars’, are now being explored as potential biomarkers of HRD.
These methods focus on identifying mutational signatures caused by the use of alternative, error-prone
repair pathways to repair DNA double-strand breaks (DSBs) in the absence of HR, and include
copy number-based methods incorporating loss of heterozygosity (LOH) [20–23], Telomeric Allelic
Imbalances (TAI) and Large-scale State Transitions (LST) [21,23–25]. Similar but more complex whole
genome sequencing-based approaches include HRDetect, a weighted model that includes features such
as microhomology-mediated deletions, base substitution, rearrangement signatures and LOH [26].
HRD-associated genomic scars have been shown to facilitate identification of both BRCA1/2-deficient
(mBRCA) as well as BRCA1/2-unrelated (wtBRCA) HRD [12,20,23,26].
The predictive value of DNA-based HRD status (defined by the presence of pathogenic variants
in BRCA1/2 and/or a specific genomic scar) for PARPi treatment benefit in EOC patients has been
evaluated in a number of clinical studies. These studies revealed that although both BRCA mutation
status and HRD status provided information regarding the magnitude of the potential treatment benefit
of a PARPi in a given patient population, these biomarkers did not sufficiently discriminate between
patients that would or would not benefit from treatment [4,5,9,12,27]. Overall, while these DNA-based
tests provide valuable proof of concept for the existence of an additional group of HRD tumors beyond
those related to BRCA1/2, DNA-based approaches also suffer from a number of important drawbacks
regarding the identification of HRD tumors. Firstly, they cannot identify all EOC patients who would
benefit from treatment with PARPi [4]. Secondly, the interpretation of modern sequencing data is far
from straightforward, as gene-based analyses often detect variants of uncertain significance (VUS)
without a clear relationship to HRD, and signature-based approaches identify a relatively large fraction
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(18%) of HR-intermediate cases in EOC [26]. Thirdly, DNA-based assays are relatively complex, costly,
and time-consuming.
As an alternative to DNA-based HRD tests, functional assays that assess the ability of replicating
tumor cells to accumulate RAD51 protein at DNA DSBs were developed for use in breast, ovarian
and endometrial cancer [28–37]. A major advantage of this approach is that RAD51-based tests detect
the current HR status of the tumor, irrespective of underlying genetics. Furthermore, the “static”
HRD status as measured by DNA-based approaches may overestimate the number of tumors that are
“functionally” HRD because they make no account for undetected reversion mechanisms [16,38–41].
Studies describing RAD51-based tests have shown that they are able to identify HRD tumors, including
but not limited to BRCA1/2-related tumors, and can detect phenotypic reversion of the HRD phenotype
in BRCA-related tumors [28–35,37,41]. In EOC, impairment of HR, as assessed in primary cultures
established from ascitic fluid, correlates with PARPi sensitivity both in vitro and in clinical studies [30,31].
A recent study using low passage, primary patient-derived tumor and ascites cells, confirmed the
predictive power of a functional HR score for platinum sensitivity [35].
The REcombination CAPacity test (RECAP) test is a RAD51-based functional test which was
previously successfully used for the analysis of HR function in solid breast and endometrial
carcinomas [36,37]. In contrast to other RAD51-based tests, the RECAP test enables the assessment
of HR on primary tumor tissue without the need to dissociate tissue and culture tumor cells, greatly
reducing the time required to perform the test.
In the current study, additional quality controls are described that enable the use of the RECAP
test in both solid EOC tumors and ascites-derived EOC tumor cells, taking into account future clinical
implementation in routine diagnostic pathology. We demonstrate that the RECAP test allows the rapid
and reliable determination of the functional HR status of EOC, and then explore its correlation with
best overall therapy response and overall survival (OS).
2. Results
2.1. REcombination CAPacity (RECAP) Test
The RECAP test has been described in detail in earlier publications [35–37], but in this study,
we adapted the protocol to make it suitable for direct use with solid tumor and ascites specimens,
removing the need for tumor dissociation and cell culture procedures (Figure 1). The RECAP test
can include up to 25 tumor specimens simultaneously, and works equally well on fresh or thawed
cryopreserved specimens (Figure S1). The use of cryopreserved samples greatly increases the clinical
utility of the RECAP test, allowing one e.g., to collect tumor tissues from different centers and perform
the test in one laboratory. The entire procedure (quality assessment and RECAP test) for a capacity
of 25 samples can be completed within two weeks and represents a 25-h hands-on workload for one
person (Table S2). The cost price of the RECAP test is more than 10-fold lower compared to DNA-based
alternatives (Table S3) and can be completed in less time than a BRCA NGS gene panel (Table S2).
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Figure 1. RECAP test procedure. (A) After surgery, tumor specimens were placed in OSE medium 
and incubated for 4 h at 37 °C on a 60 rpm rotating platform prior to irradiation with 5 Gy. Tumor 
specimens were fixed two hours after irradiation and embedded in paraffin. (B) H&E slides were 
evaluated for tissue quality (QC1) by an experienced pathologist. For ascites specimens an additional 
p53 IHC staining was performed to confirm the presence of tumor cells (QC2). All tumor specimens 
were evaluated for the presence of DNA double strand breaks based on yH2AX IHC (QC3). (C) A 
RAD51/GMN IF was performed on tumor specimens that passed the quality assessment. The RECAP 
score indicates the percentage of GMN+ cells (≥40 cells) with RAD51 foci (≥5 foci). The whole 
procedure can be performed on multiple specimens simultaneously. Abbreviations: o/n = overnight; 
RT = room temperature; QC = quality control; H&E = Hematoxylin and Eosin; IF = 
immunofluorescence; GMN+ = geminin-positive; HRP = HR-Proficient; HRI = HR-Intermediate; HRD 
= HR-Deficient. 
2.2. Identification of Homologous Recombination-Deficient Tumors Using the RECAP Test  
In total, 50 (33 solid and 17 ascites) tumor specimens (71% of the collected specimens) met the 
quality criteria and were therefore eligible for the RECAP test (Figure S2A, Table S4). Of the 50 
specimens analyzed, RECAP scores could be determined for 49 tumor specimens (98%) obtained 
from 48 patients (33 solid tumors and 16 ascites specimens; hereafter referred to as ‘RECAP 
specimens’), as one ascites specimen had to be excluded due to an insufficient number of GMN+ cells 
(<40) (Figure S2B, Table S4). Two tumor specimens were obtained from the same patient (case 18 and 
28): one at primary cytoreductive surgery (solid tumor) and one at recurrence (ascites).  
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2.2. Identification of Homologous Recombination-Deficient Tumors Using the RECAP Test
In total, 50 (33 solid and 17 ascites) tumor specimens (71% of the collected specimens) met
the quality criteria and were therefore eligible for the RECAP test (Figure S2A, Table S4). Of the
50 specimens analyzed, RECAP scores could be determined for 49 tumor specimens (98%) obtained
from 48 patients (33 solid tumors and 16 ascites specimens; hereafter referred to as ‘RECAP specimens’),
as one ascites specimen had to be excluded due to an insufficient number of GMN+ cells (<40)
(Figure S2B, Table S4). Two tumor specimens were obtained from the same patient (case 18 and 28):
one at primary cytoreductive surgery (solid tumor) and one at recurrence (ascites).
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Based on the RECAP test, ten (20%) of the 49 tumor specimens were found to be HRD (i.e., a RECAP
score 0–20%), 37 (76%) were HRP (i.e., a RECAP score 51–100%) and two tumors (4%) were HRI
(i.e., a RECAP score 21–50%). Examples of immunofluorescent stained slides are presented in Figure S3.
Median RECAP scores differed by 6% (range: 0–34%) between two independent observers, with a high
interrogator reliability for final HR group assignment (κ = 0.71). Thirty-nine of the 49 tumors (80%)
were HGSOC, and of these tumors 26% (10/39) were HRD (Figure 2A). The remaining ten tumors (20%)
were of other histologic subtypes and were all HRP, thus HRD was restricted to HGSOC in this set
of tumors.
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for DNA analysis (Figure 2B). 
  
Figure 2. RECAP scores of 49 EOC tumor specimens. (A) RECAP scores were calculated as the
average percentage of GMN+ cells with ≥5 RAD51 foci scored by two independent observers,
and specimens were classified as HRP (51–100%), HRI (21–50%) or HRD (0–20%). (B) NGS
analysis identified seven HRD tumors harboring a pathogenic variant in BRCA1 or BRCA2 with
concomitant LOH. No pathogenic variants in BRCA1 or BRCA2 were identified in HRI and HRP
tumors. BRCA1 promoter hypermethylation was observed in case 49. Pathogenic variants in other
HR genes were tested in the HRD and HRI tumors, but none were identified. Abbreviations:
HR = Homologous Recombination; HRP = HR-Proficient; HRI = HR-Intermediate; HRD = HR-Deficient;
RECAP = REcombination CAPacity; GMN+ = geminin-positive; NGS = next-generation sequencing;
HS = high-grade serous; LS = low-grade serous; M = mucinous; CC = clear cell; ET = endometrioid;
LOH = loss of heterozygosity.
2.3. Genetic Alterations in HR Genes
In an effort to determine th mol cular basis for loss of HR functionality in tumors displaying HRD,
(epi)genetic analyses were performed in nine HRD tumors. One HRD tumor could not be analyzed due
to an insufficient amount of tumor DNA. Pathogenic varian s in BRCA1, BRCA2, or BRCA1 promoter
hypermethylation were detected in eight out of nine (89%) HRD tumors in t is particul r cohort.
Six HRD tumors harbored pathogenic variants i BRCA1 with concomitant LOH of the wild-type allele
(cases 40, 41, 42, 44, 45 and 47; Figure 2B; Table S5). One HRD tumor carried a pathogenic variant
in BRCA2 with LOH of the wild-type llele (case 43; Figure 2B; Table S5), while BRCA1 pr moter
hypermethylation was observed in another HRD tumor (case 49). No pathogenic variants in BRCA1,
BRCA2 or 13 dditi nal HR-related g nes, nor BRCA1 promoter hyperme hylation or large genomic
rearrangements in BRCA1, ere detected in th remaining HRD tumor ( ase 48) nor in the two HRI
tumors (case 38 and 39). No pathogenic variants in BRCA1 a d/or BRCA2, or BRCA1 promot r
hypermethylation, were identified in any of the HRP tumors available for DNA analysis (Figure 2B).
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2.4. Clinicopathological Characteristics
Characteristics of the 48 patients for which the functional HR status of the tumor could be
established are shown in Table 1 and Table S6. The mean age of the patients was 62.5 (±1.7 SEM) years
and 38/48 (79%) of the patients had been diagnosed with FIGO stage III or IV disease. The majority of
patients were diagnosed with HGSOC 38/48 (79%). Tumor specimens were obtained from 33 ovarian
tumors (i.e., solid) and from 16 ascites specimens.
Table 1. Clinicopathological characteristics stratified for homologous recombination capacity of
the tumor.
Characteristics Total Cohortn = 48
HRP
n = 36
HRI
n = 2
HRD
n = 10
Age at diagnosis Mean (±SEM) 62.5 (±1.7) 63.6 (±1.9) 76.5 (±9.2) 55.9 (±3.2)
FIGO stage
I (I; IA; IC) 4 (8.3%) 3 (8.3%) 1 (10%)
IIB 6 (12.5%) 6 (16.7%)
III (IIIA; IIIC) 31 (64.6%) 22 (61.1%) 2 (100%) 7 (70%)
IV 7 (14.6%) 5 (13.9%) 2 (20%)
Histologic subtype
High-Grade Serous 38 (79.2%) 26 (72.2%) 2 (100%) 10 (100%)
Low-Grade Serous 3 (6.3%) 3 (8.3%)
Endometrioid 4 (8.3%) 4 (11.1%)
Clear cell 1 (2.0%) 1 (2.8%)
Mucinous 2 (4.2%) 2 (5.6%)
Tumor specimen type * Solid tumor 33 (67.3%) 24 (66.7%) 2 (100%) 7 (70%)
Ascites 16 (32.7%) 13 (36.1%) 3 (30%)
Tumor specimen
obtained *
Primary disease 39 (79.6%) 28 (75.7%) 2 (100%) 9 (90%)
Recurrent disease 10 (20.4%) 9 (24.3%) 1 (10%)
Primary treatment
strategy
Staging 3 (6.3%) 3 (8.3%)
Primary
cytoreductive
surgery
24 (50%) 18 (50%) 1 (50%) 5 (50%)
Neoadjuvant
chemotherapy 21 (43.7%) 15 (41.7%) 1 (50%) 5 (50%)
Residual tumor after
cytoreductive surgery **
Complete (0 cm) 25 (53.2%) 16 (45.7%) 2 (100%) 7 (70%)
Optimal (<1 cm) 18 (38.3%) 17 (48.6%) 1 (10%)
Not optimal (>1 cm) 4 (8.5%) 2 (5.7%) 2 (20%)
Previous cancer(s)
Ovarian and/or
breast 15 (31.2%) 10 (27.8%) 4 (40%)
None 33 (68.8%) 26 (72.2%) 1 (50%) 6 (60%)
* Two tumor specimens were derived from one patient. ** One patient with an HRP tumor did not undergo
cytoreductive surgery. Abbreviations: HRP = HR-proficient; HRI = HR-Intermediate; HRD = HR-Deficient;
FIGO = International Federation of Gynecology and Obstetrics.
Twenty-four of the 48 (50%) patients underwent primary cytoreductive surgery followed by
adjuvant platinum-based chemotherapy, while 21 of the 48 (44%) started on neoadjuvant platinum-based
chemotherapy followed by interval cytoreductive surgery (Figure S4). In 39/48 (80%) patients, RECAP
specimens were obtained at primary or interval cytoreductive surgery (i.e., primary disease) and in
10/48 (20%) patients at recurrent disease. A complete (i.e., no macroscopic rest tumor) or optimal
cytoreduction (i.e., tumor rest < 1 cm in diameter) at initial surgery was achieved in 43/47 (92%) patients.
One patient did not undergo interval cytoreductive surgery because of progressive disease after NACT
(Table 1).
2.5. The RECAP Test as a Biomarker for Platinum-Based Therapy Response
Although this study was not primarily designed to assess the relationship between the RECAP
score and clinical response to platinum-based therapy, a subgroup of patients was available that
allowed exploration of the potential differences in platinum-based therapy response between patients
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with HRD and HRP tumors. Patients were included in this analysis if they met the following criteria:
(1) RECAP classification of HRP or HRD, (2) the RECAP specimen was obtained at initial diagnosis of
ovarian cancer (at primary or interval cytoreductive surgery), (3) the patient received platinum-based
chemotherapy after the RECAP specimen was obtained, and (4) follow-up after first-line treatment
was available (Figure S5).
When considering the HGSOC patient group (Table 2), which included all of the HRD cases,
we found a trend towards a better OS for patients with HRD tumors compared to patients with HRP
tumors (Kaplan–Meier p = 0.061) (Figure 3A). When other histologic subtypes (all non-HRD) were
included, this trend was weakened but maintained (Kaplan–Meier p = 0.143) (Figure 3B).
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(A) Overall survival of 24 patients with HGSOC. (B) Overall survival of 29 patients with tumors of
diverse histologic subtype. A Log-rank (Mantel-Cox) test was performed on both groups.
Table 2. Correlation between RECAP score and clinical response.
Clinical Parameters
Diverse Histologic Subtypes HGSOC
HRP
n = 21
HRD
n = 8 HRP vs. HRD
HRP
n = 16
HRD
n = 8 HRP vs. HRD
Best overall therapy
response—
as measured with CT
scans/CA125 levels
Complete Response (CR) 17 (81.0%) 7 (87.5%) p = 0.483 12 (75.0%) 7 (87.5%) p = 1.000
Partial Response (PR) 3 (14.3%) 3 (18.8%)
Progressive Disease (PD) 1 (4.7%) 1 (12.5%) 1 (6.2%) 1 (12.5%)
Disease Free Survival
(DFS)—Time between
start of treatment and
progressive disease
Months (median) 16.0 23.8 p = 0.341 15.4 23.8 p = 0.232
Overall therapy response
last check-up—as
measured with CT
scans/CA125 levels
Complete Response (CR) 6 (28.6%) 5 (62.5%) p = 0.092 3 (18.8%) 5 (62.5%) p = 0.058
Partial Response (PR) 1 (4.7%) 1 (12.5%) 1 (6.2%) 1 (12.5%)
Stable Disease (SD) 2 (9.5%) 2 (12.5%)
Progressive Disease (PD) 12 (57.2%) 2 (25.0%) 10 (62.5%) 2 (25.0%)
Overall Survival (OS)
Yes 10 (47.6%) 6 (75%) p = 0.238 6 (37.5%) 6 (75%) p = 0.193
No 11 (52.4%) 2 (25%) 10 (62.5%) 2 (25%)
DFS and follow-up time were tested with the Mann-Whitney U test. Other clinical parameters were tested with
Fisher’s exact test. Statistically significant p-value in bold. Abbreviations: HGSOC = High-grade serous ovarian
carcinoma; HRP = HR-Proficient; HRD = HR-Deficient; CT = computed tomography.
However, patients with HRP or HRD tu ors did not differ significantly in terms of best overall
therapy response following first-line platinum-based chemotherapy (p = 1.000 HGSOC only; p = 0.483
all histologic subtypes). Median follow-up of the patients included in this analysis was 36.6 months.
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No difference was observed regarding DFS between patients with HRP and HRD tumors (p = 0.232
HGSOC only; p = 0.341 all histologic subtypes).
3. Discussion
The development of a functional biomarker test that allows reliable identification of HRD ovarian
malignancies is of broad oncologic interest, as it would facilitate the optimal selection of patients who
are most likely to benefit from treatment with PARPi. Using an optimized RECAP test, we investigated
the occurrence of HRD in 49 prospectively collected EOC. A substantial fraction of all EOCs in the
current study consisted of HGSOC, and of these 26% were classified as HRD. The prevalence of
HRD tumors amongst HGSOC that were related to BRCA1/2 deficiency (including BRCA1 promoter
hypermethylation) was broadly in line with previous reports (Table S1) [17]. However, extended
genetic analyses, including RAD51C promoter hypermethylation and mutation analysis in HR-related
genes, suggest that the proportion of HRD in HGSOC may be as high as 50% [12,17,42], a finding
also reported by others using either DNA signature-based approaches or a RAD51-based functional
test [9,12,30,31]. Yet, using a similar functional HRD test, our group and Tumiati et al. observed a
somewhat lower frequency of HRD (~30%) in HGSOC [35]. In our study, only one out of nine HRD
tumors (11%) available for sequencing could not be explained by a BRCA defect, which is somewhat
lower than expected based on previous studies [9,12]. As different methods have been used to identify
HRD tumors, several factors may contribute to the observed differences in the prevalence of HRD
tumors found in these studies. Firstly, patient cohorts differed in several aspects, such as the inclusion
of platinum-sensitive primary and recurrent disease. Secondly, the “static” HRD status as measured by
DNA-based approaches may overestimate the number of tumors that are “functionally” HRD because
of, for example, undetected reversion mechanisms [16,38–41]. However, the RECAP test may possibly
underestimate the frequency of HRD tumors, e.g., due to the inability to identify tumors that are unable
to complete HR because formed RAD51 filaments are unstable [43].
The need for improved characterization of HR status in EOC has emerged in recent PARPi
trials in which patient response was clearly related to HR status [4,5,9,12,44]. As expected, all trials
reported significant benefits in EOC patients with underlying BRCA1/2 defects (both germline and
somatic) following PARPi treatment. Intriguingly, however, the PFS hazard ratios (HR) found in
posthoc subanalysis clearly indicated that not only EOC patients with wtBRCA high HRD scores
benefit from PARPi, but also a subset of EOC patients with wtBRCA tumors showing low HRD scores
using DNA-based methods (MyChoice® HRD test). Although unlikely based on available evidence,
this outcome could be due to a PARPi response in otherwise HRP EOC. A more likely explanation is
that current DNA-based assessment of HR status is not yet sufficiently accurate. Some of the HRD
tumors might not be functional HRD and a number of functional HRD tumors might be missed when
only DNA-based approaches are considered.
Although, to date, no clinical trials have evaluated RAD51 foci formation as a biomarker for
therapy response, several retrospective studies have reported that patients with HRD tumors (defined
by a RAD51 functional test) show higher platinum sensitivity and improved survival rates [31,35].
Although our study was not designed or powered to reliably allow the predictive power of HRD
as detected by the RECAP test to be assessed, we nevertheless found a trend towards better overall
survival of HGSOC patients carrying HRD tumors compared to HRP tumors. Formally, we cannot
rule out that this better overall survival is driven by the high frequency of BRCA-related HRD tumors
(seven out of eight) for which improved therapy outcome has previously been reported.
Additional studies will be required to determine whether the RECAP test is a reliable,
comprehensive and efficient biomarker test for a PARPi response. Ideally, these studies should
include a comprehensive comparison of the performance of various HRD biomarker tests with respect
to sensitivity, specificity, take-rate and costs.
The RECAP test as described here has many advantages over DNA-based tests in terms of
cost, speed of turnaround and simplicity of analysis once implemented. The cost per sample for the
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RECAP test is more than 10-fold lower than the costs of running a BRCA NGS gene panel (Table S3).
In addition, the RECAP test can be completed in less time than a BRCA NGS gene panel (Table S4).
Another major strength of the RECAP test is that it allows identification of HRD tumors independently
of BRCA status, while correctly assessing BRCA-related tumors with reversion mutations as being
HRP [36,37,41], in contrast to DNA-based tests [16,38–40]. In our study, the RECAP test identified
all tumors with BRCA defects as HRD, further underlining the high reliability of the test. As some
laboratories nowadays offer BRCA tumor testing to identify patients for follow- up germline BRCA
testing, the use of the RECAP test as a prescreen for BRCA testing would substantially reduce the
number of tumors to be sequenced to identify these patients.
The RECAP test is not without its limitations. It relies on fresh or cryopreserved tumor specimens
and requires induction of DSBs by ionizing radiation or chemical compounds such as platinum-based
compounds or PARPi [29,30,32,33,36,37]. The percentage of samples that did not pass our stringent
quality control (29%) is higher than reported for DNA-based analyses (15%) [4,9].
Initial set-up and implementation in a routine diagnostic setting might therefore be challenging
in some laboratories. Recently, an attractive adaptation of the RECAP procedure was proposed that
maintains the advantages of the test while avoiding the drawbacks. This new approach is innovative
because it now allows assessment of RAD51 foci in FFPE breast tumor samples directly [45,46]. We now
propose to establish whether the use of FFPE material can serve as a reliable substitute for fresh tumor
tissue, comparing fresh tumor specimens and matching archival FFPE tumor blocks on RAD51 scores,
ideally in large cohorts of different tumor types. Should the FFPE-based method prove to be as reliable
as the current RECAP test, the use of RAD51 as a biomarker for the identification of HRD tumors will
become feasible in many more diagnostic laboratories, facilitating the rapid and reliable identification
and selection of patients who may derive the most benefit from PARPi treatment.
In conclusion, we show that functional analysis of HR status in EOC by the RECAP test enables fast
and reliable identification of tumors with a deficiency in HR. The RECAP test is therefore an attractive
alternative to DNA-based HRD tests and warrants further development as a clinical grade test.
4. Materials and Methods
4.1. EOC Patient Material
Fresh tumor tissue or ascites fluid from patients with primary or recurrent EOC who underwent
cytoreductive surgery or drainage of ascites fluid at Leiden University Medical Center (LUMC) was
prospectively collected if sufficient material was available for research. In total, 70 specimens (43 solid
tumors and 27 ascites) were obtained from 66 patients between June 2010 and July 2017.
After surgical removal of the tumor, macroscopic dissection was performed for diagnostic purposes
at the Department of Pathology. When available, a tumor tissue fragment (minimum of 0.5–1 cm3)
was transferred to OSE medium (Wisent Bioproducts, cat. 316-030-CL) supplemented with 10% Fetal
Bovine Serum (FBS) (Bodinco), 1% penicillin (100 U/mL) and streptomycin (0.1 mg/mL), kept at 4 ◦C
and processed within 24 h of surgical resection (Figure 1A). Ascites was collected in fluid drainage bags,
kept at 4 ◦C and used within 24 h after fluid drainage. Surplus tumor specimens were cryopreserved
to enable comparison of test outcomes in fresh versus cryopreserved specimens (see below).
All specimens were coded with a unique research code. The study protocol has been approved by
the Medical Ethics Committee of the LUMC on 7 February 2011 and 24 May 2017 (P10.226 and G17.041)
and specimens were handled according to the Code for Proper Secondary Use of Human Tissue in the
Netherlands as established by the Dutch Federation of Medical Scientific Societies.
4.2. Cryopreservation and Thawing of Tumor Specimens
Surplus tumor specimens were cryopreserved in ampules containing 500 µL Recovery Cell Culture
Freezing Medium (Gibco, cat. 12648010). Cells isolated from ascites were collected and cryopreserved
at approximately 10 million cells per ampule containing 500 µL of Recovery Cell Culture Medium.
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Ampules were placed in a freezing container (Nalgene Mr. Frosty, Sigma, cat. C1562) overnight at
−80 ◦C before transfer to liquid nitrogen storage. Cryopreserved tumor specimens were thawed quickly
in a 37 ◦C water bath. Solid tumor specimens were washed in pre-warmed (37 ◦C) OSE medium
containing 40% FBS by gentle rotation of the tube for 5 min and subsequently transferred to 2.5 mL
OSE medium supplemented with 10% FBS and pen/strep, and next incubated on a 60 rpm rotation
platform at 37 ◦C in a 5% CO2 humidified atmosphere overnight prior to irradiation. After thawing,
cells from ascites were collected by centrifugation (1000 rpm, 5 min), washed for 5 min in the presence
of pre-warmed (37 ◦C) OSE medium containing 40% FBS, collected by centrifugation and supplemented
in culture medium for subsequent use (see below).
4.3. REcombination CAPacity (RECAP) Test
The RECAP test was performed according to our previously published method [37], but was
adapted for ascites specimens as follows: Tumor cells were obtained by centrifugation (5 min, 1000 rpm)
of one liter of ascites fluid, cell pellets were then washed in lysis buffer (155 mM NH4CL/21 mM Tris)
to remove red blood cells, and after a second round of centrifugation, cell pellets were washed in OSE
medium supplemented with 10% FBS and penicillin-streptomycin (pen/strep). Approximately ten
million cells were seeded in 20 mL OSE medium supplemented with 10% FBS and pen/strep prior to
incubation and irradiation. After fixation, cells were centrifuged (1000 rpm, 5 min), washed in 70%
ethanol and embedded in Shandon Cytoblock gel (Thermo Scientific, Waltham, MA USA, cat. 7401151).
In addition, all tumor specimens were subjected to quality assessment.
4.4. Quality Assessment
To determine whether the tissue quality and the number of tumor cells was sufficient for analysis
in the RECAP test, three quality assessments were applied as summarized in Figure 1B and Figure S2A.
First, the quality of the tumor specimen was assessed by a pathologist (TB) using a hematoxylin
and eosin (H&E) stained section of the irradiated tumor used in the RECAP test (quality control 1,
QC1). The tissue quality (1–2 = poor, 3–4 = moderate and 5–6 = good) was determined on the basis of
the sum of the tissue vitality (1 = poor, 2 = moderate and 3 = good) and tumor percentage (0 = <5%,
1 = 5–20%, 2 = 21–50% and 3 = >50%). When a tumor specimen had a total tissue quality score of ≤2,
cryopreserved tissue was thawed, and the procedure was repeated. If the total tissue quality score of
this sample was also ≤2, the specimen was excluded from further analysis (Table S4).
To aid in the identification of tumor cells in ascites specimens, we included a p53 immunostaining
as a second quality control (QC2) since over 98% of HGSOC have been reported to be TP53-mutant [47].
Immunohistochemistry staining for p53 (Agilent Dako, cat. M7001) was performed as described
previously [48]. A pathologist (TB) used a combination of H&E and p53-IHC stained slides to either
include (sufficient cancer cells available) or exclude (insufficient cancer cells available) ascites cases
from the study (Table S4).
Third, yH2AX immunostaining was included as a proxy for the presence of DNA DSBs (quality
control 3, QC3). Immunohistochemistry was performed as described previously [48]. The primary
yH2AX antibody (mouse, monoclonal, clone JBW301, Sigma-Aldrich, Zwijndrecht, The Netherlands,
cat. 05-636) was diluted 1:40,000 in block buffer and incubated at room temperature (RT) o/n.
The secondary antibody (BrightVision poly-HRP-anti-Mouse, Immunologic, Duiven, The Netherlands,
cat. VWRDPVVM0110HRP) was incubated for one hour at RT according to the manufacturers’ protocol.
A pathologist (TB) scored the slides based on the presence (inclusion of the sample) or absence
(exclusion of the sample) of yH2AX foci.
A total of 70 EOC specimens (43 solid tumors and 27 ascites specimens) (Figure S2A) were
collected from 66 patients. Among these tumor specimens 47/70 passed quality control according
to QC1 (Materials and Methods, 30 solid and 17 ascites). Of the fresh specimens that failed QC1,
11 (3 solid and 8 ascites) could still be included by using cryopreserved material (Figure S1), resulting in
a total of 58/70 (33 solid and 25 ascites) tumor specimens that passed QC1. Seventeen of the 25 ascites
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specimens passed QC2 (Materials and Methods, p53 staining). All tumor specimens were positive for
yH2AX foci and therefore passed QC3.
4.5. Immunofluorescence Staining for RAD51 and Geminin
Immunofluorescence staining for RAD51 (RAD51 (mouse, monoclonal, GeneTex, Alton Pkwy
Irvine, CA USA, cat. GTC70230)) and geminin (rabbit, polyclonal, ProteinTech, Manchester,
United Kingdom, cat. 10802-1-AP)) was performed as described previously [37], with the following
modifications: Tissue sections were incubated at 60 ◦C overnight on SuperFrost Plus microscope slides
(75 × 25 mm, VWR, Amsterdam, The Netherlands, cat. 631-0108) prior to immunofluorescence staining
and no EdU immunostaining was performed (Figure S3).
4.6. Scoring of RECAP Tumor Specimens
The scoring of RECAP tumor specimens was blinded for genetic data (BRCA status). Tissue
sections stained for DAPI, geminin (G2/S phase marker) and RAD51 were manually scored using a
Zeiss Axio Imager D2 microscope with a HXP 120C light source. DAPI was used to localize tumor
cells in the tissue section based on morphology. Cells were considered geminin-positive (GMN+) if
the nucleus was homogenously stained. GMN+ cells were considered RAD51+ if there were at least
5 nuclear foci visible. A minimum of 40 GMN+ cells, randomly chosen in vital tumor areas (defined by
the lack of necrosis visible with DAPI) were scored. Specimens with less than 40 GMN+ cells were
excluded from the analysis (Figure 1C and Figure S2B).
The RECAP score is the average percentage score, for two independent observers, of GMN+
cells with RAD51 foci. Tumors were allocated to one of three groups: HR-Proficient (HRP; 51–100%),
HR-Intermediate (HRI; 21–50%) or HR-Deficient (HRD; 0–20%). The two hour post-irradiation
incubation time point and the thresholds for HR status assignment were determined in a previous
study on breast tumors [37]. In this and subsequent studies on breast and endometrial carcinomas these
settings allowed unequivocal discrimination between BRCA wildtype and BRCA1/2 deficient tumors
(including those with promoter hypermethylation of BRCA1) while identifying an additional group of
HRD tumors not related to BRCA1/2 [36,37]. In EOC, with these settings RAD51 foci formation was
observed in the majority of replicating tumor cells in BRCA wildtype tumors while correctly identifying
BRCA1/2 deficient tumors. The Cohen kappa coefficient (k) was used to measure interobserver and
intertest agreement.
4.7. Tumor DNA Isolation
Tumor DNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue blocks either by
taking three 0.6 mm tumor cores or by microdissection of tumor areas with at least 70% tumor cells
(10 mm slides). Fully automated DNA isolation was performed using the Tissue Preparation System
(Siemens Healthcare Diagnostics) as described previously [37]. An H&E slide (5 µm) was prepared
for each FFPE tissue block to determine tumor percentage prior to tumor DNA isolation. The Qubit
dsDNA HS Assay Kit was used for DNA quantification according to manufacturer’s protocol (Qubit 2.0
Fluorometer, Invitrogen, Waltham, MA USA, cat. Q32851).
4.8. Next-Generation Sequencing
Next-generation sequencing (NGS) was performed using 40 ng of tumor DNA per sample isolated
from FFPE tissue blocks. The mean tumor cell percentage of included samples was 62% (range:
10–90%). All tumors (HRD, HRI, and HRP) have been sequenced for BRCA1 and BRCA2 and analyzed
for promoter hypermethylation of BRCA1. The non-BRCA HRD tumor and the two HRI tumors were
subsequently analyzed for pathogenic variants in 13 additional HR-related genes and large genomic
rearrangements in BRCA1.
The custom Ampliseq HDR15v1-panel (Thermo Fisher) was used for variant detection in the
coding exons of the following HR-associated genes: ATM (not covered by design: exon 25 (1225–1231),
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exon 36 (1813–1821), exon 52 (2576–2596)), BARD1, BRCA1, BRCA2, BRIP1, CDK12 (not covered
by design: exon 1 (294–302)), CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C (not
covered by performance, exon 5 (236–241)), RAD51D (not covered by performance, exon 5 (130–160)),
and RAD54L. Details on request (TVW, NS). Mutation and LOH analysis of the NGS data was performed
as described previously by de Jonge et al. [49]. Variants were categorized using the 5-tier pathogenicity
classification according to Plon et al.: Class 1 = benign, Class 2 = likely benign, Class 3 = variant of
unknown significance (VUS), Class 4 = likely pathogenic, and Class 5 = pathogenic [50].
4.9. BRCA1 Promoter Hypermethylation by MS-MLPA
Analysis of BRCA1 promoter hypermethylation by MS-MLPA was performed as described
previously [37].
4.10. BRCA1 MLPA
Copy number variant (CNV)-MLPA was performed as described previously [49].
4.11. Clinical Response Evaluation and Follow-Up
Clinical follow-up data were retrospectively collected for all patients whose tumor specimens
had an informative RECAP score. Ovarian cancer staging was performed according to the 2014
International Federation of Gynecology and Obstetrics (FIGO) guidelines [51]. The study was
conducted in accordance with the Declaration of Helsinki and the Dutch Code of Good Conduct.
Primary therapy response after first-line treatment and overall therapy response at the last
check-up were assessed by physical and gynecological examination, measurement of tumor marker
CA125 and/or computed tomography (CT) scans according to the RECIST version 1.1 guideline [52].
In patients with CA125 levels < 35 KU/L [53] and no clinical signs of tumor by physical and gynecological
investigation, a standard CT scan was not always performed after first-line treatment (Figure S4).
Primary therapy response after first-line treatment was noted as a complete or partial response, or as
stable or progressive disease according to the WHO criteria. The best overall therapy response is
defined as the best recorded response from the start of the treatment to disease progression/recurrence.
Disease-Free Survival (DFS) was defined as the period between start of treatment, i.e., primary
cytoreductive surgery, staging procedure or start of platinum-based chemotherapy, and the first
observation of recurrent or progressive disease or death due to any cause, whichever occurred
first. A patient was considered platinum-sensitive when no recurrence or progression was noted for
≥6 months after the last chemotherapy. When recurrence or progression occurred within <6 months
after the last chemotherapy, a patient was considered platinum-resistant. Overall Survival (OS) was
determined from the date of start of treatment i.e., date of primary surgery or start of platinum-based
chemotherapy to the date of death from any cause. Follow-up time was calculated from the date of
start of treatment until the last check-up before cut-off for the final analysis or the date of death from
any cause (Figure S4).
4.12. Statistical Analysis
Statistical analysis of clinical data was performed with SigmaStat 3.5 (Systat Software Inc, San Jose,
CA, USA) and Graphpad Prism 8.0 (Graphpad Software, San Diego, CA, USA). Student’s t-tests were
performed on numerical data when normality criteria were met, otherwise Mann-Whitney U tests were
performed. Chi-square tests were performed on categorical data when normality criteria were met and
Fisher’s exact tests were performed when data were not normally distributed. Kaplan–Meier plots of
follow-up were generated in Graphpad Prism 8.0 for OS. Images were produced with GraphPad Prism
8.0 and Adobe Creative Suite CS6 (Adobe, San Jose, CA, USA).
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5. Conclusions
In this manuscript we describe the use of the REcombination CAPacity (RECAP) test to identify
HRD ovarian carcinomas. We found that all HRD ovarian carcinomas in our cohort were of the
high-grade serous (HGSOC) histologic subtype. The RECAP test showed that 26% (10/39) of HGSOCs
were HRD. Of the HRD tumors available for sequencing, 8/9 showed pathogenic BRCA1/2 variants or
BRCA1 promoter hypermethylation, indicating that the RECAP test matches and exceeds the detection
capacity of DNA-based tests, but more rapidly and at lower costs. Furthermore, we found a trend
towards better overall survival of HGSOC patients with HRD tumors compared to patients with
HR proficient tumors. Overall, we show that the RECAP test is rapid, reliable, and as such, a good
alternative to DNA-based tests.
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illustrating inclusion criteria for RECAP specimens and take-rate, Figure S3: Microscopy illustration of HRP and
HRD solid and ascites ovarian tumor specimens classified by the RECAP test, Figure S4: Timeline treatment
procedure EOC patients, Figure S5: Flowchart illustrating patient inclusion for comparison of RECAP scores
with therapy response, Table S1: Identification of HR-deficient tumors by functional and genomic analyses,
Table S2: Estimated workload of BRCA next-generation sequencing gene panel testing versus the RECAP test,
Table S3: Estimated cost prices for a BRCA next-generation sequencing gene panel versus the RECAP test, Table S4:
Excluded tumor specimens based on tissue quality, p53 status or the RECAP test, Table S5: Pathogenic variants in
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RECAP test.
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